| Babesiosis: appreciating the pathophysiology and diverse sequela of the infection JF Ortiz, PW Millhouse, ÁM Cox, L Campoverde, A Kaur, M Wirth, A Atoot Cureus 12 (10), 2020 | 8 | 2020 |
| A unique case of pyruvate carboxylase deficiency J Hidalgo, L Campoverde, JF Ortiz, S Ruxmohan, A Eissa-Garcés Cureus 13 (5), 2021 | 6 | 2021 |
| Osteogenic sarcoma of the head and neck: Is chemotherapy needed? S Bialick, L Campoverde, JAO Gallegos, P Barreto-Coelho, A Watson, ... Current treatment options in oncology 24 (5), 528-541, 2023 | 4 | 2023 |
| KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor. S Bialick, BE Rose, AP Espejo-Freire, P Barreto Coelho, PA Costa, ... Journal of Clinical Oncology 40 (16_suppl), 11514-11514, 2022 | 2 | 2022 |
| Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis F Batalini, LL DaSilva, L Campoverde, ACM Comini, BM Carvalho, ... Chinese Clinical Oncology 12 (3), 21-21, 2023 | 1 | 2023 |
| Expanding the spectrum of neoplasms harboring EWSR1:CREM fusion as detected by a real-world clinical genomics platform. L Campoverde, MG Evans, A Elliott, F Camacho, J Adler, MJ Oberley, ... Journal of clinical oncology 41 (16_suppl), e15061-e15061, 2023 | 1 | 2023 |
| Case report: The activity of multi-kinase VEGF inhibitor, Pazopanib, in metastatic undifferentiated round cell sarcomas harboring EWSR1:: CREM fusion: clinicopathological … L Campoverde, F Camacho, F Alessandrino, MG Evans, A Elliot, ... Frontiers in oncology 13, 2023 | 1 | 2023 |
| Pancreatic Acinar Cell Carcinoma in the Setting of a BRCA1 Germline Mutation L Campoverde, M Vyas, A Bullock Annals of Internal Medicine: Clinical Cases 1 (7), e220596, 2022 | 1 | 2022 |
| Thrombosis Rates and Use of Thromboprophylaxis after Discharge from Gynecologic Cancer-Related Surgery LE Campoverde, A Mercadel, DM Kaplan, A Trabolsi, T Plate IV, ... Blood 142, 5530, 2023 | | 2023 |
| Predictors and Timing of Venous Thromboembolism in Lung Cancer T Plate IV, A Trabolsi, RS Kronenfeld, LE Campoverde, DM Kaplan, ... Blood 142, 2649, 2023 | | 2023 |
| Predictors and Timing of Venous Thromboembolism in Lymphoma A Trabolsi, T Plate IV, RS Kronenfeld, LE Campoverde, DM Kaplan, ... Blood 142, 2642, 2023 | | 2023 |
| Predictors and Timing of Venous Thromboembolism in Lung Cancer P Thomas, A Trabolsi, RS Kronenfeld, LE Campoverde, DM Kaplan, ... BLOOD 142, 2023 | | 2023 |
| Targeting Complement Inhibition in Cold Hemolysis; A Multifaceted Approach Using Sutimlimab and Washed Red Cell Transfusions LE Campoverde, JJ Byrnes, DM Byrnes Blood 142 (Supplement 1), 5194-5194, 2023 | | 2023 |
| Clinical-pathological features and treatment outcomes in Hispanic/Latino patients with advanced renal cell carcinoma at a single institution. JA Ocejo Gallegos, A Murray, S Jones, RL Frias, J Noy, L Campoverde, ... Journal of Clinical Oncology 41 (16_suppl), e16554-e16554, 2023 | | 2023 |
| Epidemiologic and socioeconomic characteristics of Hispanics diagnosed with metastatic renal cell carcinoma in the US. A Murray, JA Ocejo Gallegos, S Jones, RL Frias, J Noy, L Campoverde, ... Journal of Clinical Oncology 41 (16_suppl), e16555-e16555, 2023 | | 2023 |
| Towards the improvement of breast cancer management based on EUSOMA quality indicators: Insights from a 15-year institutional experience. L Paulina, L Campoverde, V Bautista, S Saenz, A Caicedo Journal of Clinical Oncology 41 (16_suppl), e13662-e13662, 2023 | | 2023 |
| Correlation between Oncotype DX, Predict, and Nottingham Prognostic Index on HR+, HER2-early breast cancer treatment: The current value of molecular testing. L Campoverde, F Camacho, A Sanchez, P Lugo Journal of Clinical Oncology 41 (16_suppl), 1601-1601, 2023 | | 2023 |
| Epidemiological characterization of renal cell carcinoma in Hispanics: A single US center cohort study AA Murray, JAO Gallegos, S Jones, J Noy, RL Frias, LE Campoverde, ... Cancer Research 83 (7_Supplement), 722-722, 2023 | | 2023 |
| Comparative effectiveness of systemic treatments in desmoid tumors. PA Costa, A Arora, H Tan, Y Fernandez, L Campoverde, P Barreto Coelho, ... Journal of Clinical Oncology 40 (16_suppl), e23534-e23534, 2022 | | 2022 |
| Evaluation of homologous recombination deficiency biomarkers in patients with ovarian cancer treated with PARP inhibitors. L Campoverde, L Lopes Da Silva, H Silveira, W Coelho Nogueira, ... Journal of Clinical Oncology 40 (16_suppl), e17615-e17615, 2022 | | 2022 |
